铂耐药和铂敏感上皮性卵巢癌中ERCC1、survivin蛋白的表达及临床应用价值

The Protein Expression of ERCC1 and Survivin in Epithelial Ovarian Carcinoma and Their Clinical Significance

目的探讨铂耐药和铂敏感上皮性卵巢癌患者ERCC1蛋白、生存素(survivin)蛋白的表达及其与临床病理特征及化疗敏感性之间的关系。方法采用免疫组织化学法检测64例上皮性卵巢癌组织中ERCC1和survivin的表达情况。结果铂敏感与铂耐药患者之间、ERCC1阳性表达与阴性表达患者之间以及survivin阳性表达与阴性表达患者之间在发病年龄、FIGO分期、病理类型、组织学分级、有无淋巴结和/或脉管转移等方面的组间差异均无统计学意义(P>0.05)。铂耐药患者ERCC1阳性表达率(67.85%,19/28)高于铂敏感患者(25.00%,9/36)(P=0.001)。铂耐药患者survivin阳性表达率(78.57%,22/28)与铂敏感患者(75.00%,27/36)差异无统计学意义(P=0.74)。ERCC1表达与survivin表达间无相关关系(rs=0.12,P=0.36)。ERCC1与survivin共表达的患者中发生铂耐药的比例(65.22%,15/23)与ERCC1单表达患者中发生铂耐药患者的比例(80.00%,4/5)间差异无统计学意义(P=0.91)。结论测定上皮性卵巢癌组织中ERCC1的表达对预测铂耐药的发生有较大价值;survivin蛋白对预测铂耐药暂无肯定价值。

Objective To investigate the protein expression of ERCC1（excision repair cross complementation group 1） and survivin gene in platinum-resistant and platinum-sensitive epithelial ovarian carcinoma（EOC）,and to explore the relationship among ERCC1 expression,survivin expression,the major clinicopathological charactetistics as well as platinum sensitivity.Methods Expression of ERCC1 and survivin were detected in 64 EOC tissues by immunohistochemical method.Results No significant differences were found in patients’ age,FIGO stage,pathological type,histological grade,pelvic lymph node and/or vessel infiltration,in all of three pairs of comparison.They were platinum-sensitive group vs.platinum-resistant group,ERCC1-positve group vs.ERCC1-negative group and surviving-positive group vs.survivn-negative group（all P〉0.05）.The positive rate of ERCC1 expression（67.85%,19/28） in platinum-resistant patients’ tissues was significantly higher than that in platinum-sensitive patients’ tissues（25.00%,9/36）（P=0.001）.While the positive rate of survivin in platinum-resistant patients’ tissues（78.57%,22/28） was slightly higher than that of in platinum-sensitive patients’ tissues（75.00%,29/36）,however without significant（P=0.74）.No evidence was found that the expression of ERCC1 correlate with the expression of survivin（rs=0.12,P=0.36） too.The proportion of platinum-resistant in patients with coexpression of ERCC1 and surviving（65.22%,15/23） was insignificantly lower than that of in patients with single expression of ERCC1（80.00%,4/5）（P=0.91）.Conclusion Expression of ERCC1 in EOC patients’ tumor tissue could be a predictive indicator fortheir platinum susceptibility and it might be helpful for prevention and reverse of platinum resistance in clinical practice.The expression of survivin seems of no definite value in prediction of platinum susceptibility.